Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.
Low self-reported functional status was associated with higher cardiometabolic risk among individuals 45 years and older with HIV, according to data from REPRIEVE, a phase 3 multinational cohort, published in Clinical Infectious Diseases.
While past studies have demonstrated similar findings within a specific country or geographic region, none included a multinational population to compare functional impairment between Global Burden of Disease (GBD) regions or to explore how different factors that contribute to varying impairment may exist among regions.
“Indeed, the factors that may contribute to physical function burdens in higher income countries may be markedly different than those that contribute to functional burden in Sub-Saharan Africa or Asia,” the study authors said. “Furthermore, the HIV epidemics in these regions differ with respect to the proportion of women and the timing and type of antiretroviral therapy (ART) that may influence the development of other comorbidities.”
This study included adults aged 40 to 75 years living with HIV who were receiving ART for at least 6 months; they were randomized to either pitavastatin (Livalo) calcium 4 mg daily or placebo for the study.
A total of 7736 participants were recruited from more than 100 locations in 12 countries. All participants had a CD4 T-cell count above 100 cells/mcL, had no known cardiovascular disease, and had low to moderate traditional risk of atherosclerotic cardiovascular disease (ASCVD).
Fifth-three percent of the participants were from high-income countries, 65% were male, and 48% had received ART for at least 10 years. The Duke Activity Status Instrument (DASI) was used to categorize participants based on impairment level: none, some, moderate, and severe.
Sixty-four percent reported no impairment, 28% some impairment, and 8.2% moderate impairment; 0.31% reported severe impairment. The median (IQR) DASI score was 58.2 (50.2-58.2), the highest score available that reflects the highest functional status, the authors noted.
Adjusted analyses showed significantly more frequent functional impairment among participants from South Asia, with 96% of participants from this area reporting at least some impairment vs participants from high-income regions, Latin America and the Caribbean, Southeast and East Asia, and Sub-Saharan Africa.
While differences were noted between GBD regions, other factors associated with greater functional impairment included:
The authors also found greater proportions of higher ASCVD risk scores (> 7.5%) among participants living with HIV reporting at least some functional impairment.
Additionally, moderate to severe impairment was associated with a 45% greater risk of having metabolic syndrome (HR, 1.45; 95% CI, 1.20-1.77) and a 15% greater risk of having the high waist circumference component of metabolic syndrome (HR, 1.15; 95% CI, 1.10-1.19).
“The associations between DASI and cardiometabolic risk suggest that a measure of functional status may improve risk prediction,” the authors explained. “These longitudinal associations will be further investigated over REPRIEVE trial follow-up.”
Reference
Erlandson KM, Fitch KV, McCallum SA, et al. Geographical differences in the self-reported functional impairment of people with HIV and associations with cardiometabolic risk. Clin Infect Dis. Published online February 15, 2022. doi:10.1093/cid/ciac098
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More